Covid-19 man­u­fac­tur­ing roundup: Bharat Biotech turns to oth­er pro­duc­ers to up sup­ply; Brazil, Ar­genti­na land mR­NA re­gion­al hubs

Bharat Biotech is ready to start man­u­fac­tur­ing dos­es of its Covid-19 vac­cine — named Co­v­ax­in — at an as­so­ciate firm’s Man­jari site, Busi­ness-Stan­dard re­port­ed Wednes­day.

The BioVet plant was ac­quired from a Mer­ck sub­sidiary as that com­pa­ny left its In­dia op­er­a­tions be­hind. Right now, en­gi­neer­ing batch­es are be­ing run to test the equip­ment’s func­tion­al­i­ty, a source told the out­let.

The com­pa­ny is like­ly to pro­duce 55 mil­lion dos­es of the jab amount by Oc­to­ber. In Au­gust, there were 35 mil­lion dos­es man­u­fac­tured.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER